Double Blind, two dose, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
Experimental medication to improve cognition in schizophrenia patients
Sponsor: NIH - NIMH
Enrolling: Male and Female Patients
IRB Number: 7370
U.S. Govt. ID: NCT02978599
Contact: James Gangwisch PhD: 646-774-8433 / jeg64@columbia.edu
Additional Study Information: AVL-3288 is an experimental medication that effects the nicotine receptors in the brain that isbeing initially developed for the treatment of cognitive problems in patients with schizophreniaaccompanied. To date, no specific treatments for cognitive deficits in schizophrenia exist and approvedtherapies do not satisfactorily improve cognition.
This study is closed
Investigator
Jeffrey Lieberman, MD
Do You Qualify?
Do you suffer from schizophrenia? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
James Gangwisch PhD
jeg64@columbia.edu
646-774-8433
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE